tarextumab   Click here for help

GtoPdb Ligand ID: 8453

Synonyms: OMP-59R5
Compound class: Antibody
Comment: Tarextumab is fully human IgG2 monoclonal antibody targeting Notch receptors 2 and 3.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain of tarextumab reveals 100% match with sequences patented in US8226943 B2 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Gurney AL, Hoey TC, van der Horst ETH, Sato AK, Liu YC, Bruhns MF, Lewicki JA. (2012)
Antibodies to notch receptors.
Patent number: US8226943 B2. Assignee: Oncomed Pharmaceuticals, Inc.. Priority date: 08/07/2008. Publication date: 24/07/2012.
2. Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS et al.. (2019)
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Cancer Med, 8 (11): 5148-5157. [PMID:31347292]
3. Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, Xu L, Dupont J, Stagg RJ, Tolcher A. (2019)
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Invest New Drugs, 37 (4): 722-730. [PMID:30591982]